HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HSDT
Solana Company
There isn't enough reported data to score HSDT yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HSDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
HSDT's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HSDT PE Valuation
HSDT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HSDT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect HSDT's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HSDT Earnings Per Share
HSDT has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HSDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.4M | +382% |
| Q2 2026 | $2.5M | +5774% |
| Q1 2026 | $3.6M | +7290% |
| Q4 2025 | $5.2M | +3339% |
| Q3 2025 | $697K | +1267% |
| Q2 2025 | $43K | -76% |
| Q1 2025 | $49K | -64% |
| Q4 2024 | $152K | +13% |
HSDT's revenue has grown year over year for five quarters in a row: $3M last quarter, up 382% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3091% | +8177 points |
| Q2 2026 | -1293% | +6432 points |
| Q1 2026 | -2751% | +5435 points |
| Q4 2025 | -3846% | -1775 points |
| Q3 2025 | -5086% | +2894 points |
| Q2 2025 | -7726% | -5929 points |
| Q1 2025 | -8186% | -5655 points |
| Q4 2024 | -2070% | -394 points |
HSDT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HSDT has the stronger cash trend. Its trailing FCF is down 72% versus its history, compared with HIMS at down 84%.
HSDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$2.4M | -$341K |
| Q3 2024 | -$2.8M | -$313K |
| Q2 2024 | -$2.9M | -$150K |
| Q1 2024 | -$3M | +$203K |
| Q4 2023 | -$2M | +$104K |
| Q3 2023 | -$2.5M | +$1.4M |
| Q2 2023 | -$2.7M | +$933K |
| Q1 2023 | -$3.2M | +$1.5M |
HSDT has burned cash in almost every quarter: −$22M over the past year, against −$11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HSDT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HSDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +102% | +5.1K shares |
| 1 year | +1032% | +9.2K shares |
| 3 years | +18557% | +10K shares |
HSDT has 10,075 diluted shares, up 1032% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.8M |
| Q2 2026 | $2.3M |
| Q1 2026 | $3.5M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HSDT Net Leverage
HSDT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HSDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 19.6 | Oversold |
HSDT's weekly RSI is 33 (neutral) and its Stochastic is 20 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HSDT PE vs Healthcare Sector
HSDT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HSDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.30 | 18% below |
| 20 week MA | $2.10 | 10% below |
| 50 week MA | $2.24 | 16% below |
| 100 week MA | $91.2 | 98% below |
| 200 week MA | $2,397.1 | 100% below |
HSDT is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HSDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,246,875.0 | $540,750.0 | -57% |
| 2021 | $540,750.0 | $208,500.0 | -61% |
| 2022 | $208,500.0 | $8,325.0 | -96% |
| 2023 | $8,325.0 | $6,030.0 | -28% |
| 2024 | $6,030.0 | $525.0 | -91% |
| 2025 | $525.0 | $2.78 | -99% |
| 2026 YTD | $2.78 | $1.89 | -32% |
HSDT has the edge over HIMS on returns for 2026, with the stronger performance.